The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management
Open accessAbstract
Primary sclerosing cholangitis (PSC), first described in the mid-1850’s, is a complex liver that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis, associated with chronic inflammation of the biliary epithelium, resulting in multi-focal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood which in part explains a lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Self-citationCairns, S. R., Scholefield, J. H., Steele, R. J., Dunlop, M. G., Thomas, H. J. W., Evans, G. D., Eaden, J. A., Rutter, M. D., Atkin, W. P., Saunders, B. P., et al. (2010) · Gut · doi:10.1136/gut.2009.179804 · Cited by 1,141
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890 · cited 2×
“Therefore, it is important to carefully exclude the presence of malignancy.(30) Future studies should help clarify the prevalence and outcomes of patients with PSC who have increased levels of IgG4 who do not meet the criteria for IAC.”
BackgroundSelf-citationNatural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Chapman, R. W., Arborgh, B. A., Rhodes, J. M., Summerfield, J. A., Dick, R., Scheuer, P. J., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.10.870 · Cited by 732
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720
Self-citationGuo, S., Al-Sadi, R., Said, H. M., & Ma, T. Y. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.10.014 · Cited by 719
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Ghoreschi, K., Jesson, M. I., Li, X., Lee, J. L., Ghosh, S., Alsup, J. W., Warner, J. D., Tanaka, M., Steward-Tharp, S. M., Gadina, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003668 · Cited by 645
Soetikno, R. M., Lin, O. S., Heidenreich, P. A., Young, H. S., & Blackstone, M. O. (2002) · Gastrointestinal Endoscopy · doi:10.1067/mge.2002.125367 · Cited by 623
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
Self-citationDarwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597
Self-citationPardi, D. S., Loftus, E. V., Kremers, W. K., Keach, J., & Lindor, K. D. (2003) · Gastroenterology · doi:10.1053/gast.2003.50156 · Cited by 562
Self-citationPenna, C., Dozois, R., Tremaine, W., Sandborn, W., LaRusso, N., Schleck, C., & Ilstrup, D. (1996) · Gut · doi:10.1136/gut.38.2.234 · Cited by 561
Boberg, K. M., Chapman, R. W., Hirschfield, G. M., Lohse, A. W., Manns, M. P., & Schrumpf, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.002 · Cited by 555 · cited 2×
“The simplified International Autoimmune Hepatitis Group scoring system can aid in diagnosis of AIH, but it is not recommended for diagnosis of AIHPSC.(56) AIH-PSC should be suspected in patients with abnormal cholangiograms that indicate PSC, biochemical features of AIH (increased antibody titers or levels of transami…”
BackgroundFarraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.035 · Cited by 494
Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481
Tung, B. Y., Emond, M. J., Haggitt, R. C., Bronner, M. P., Kimmey, M. B., Kowdley, K. V., & Brentnall, T. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00008 · Cited by 469
Fickert, P., Fuchsbichler, A., Wagner, M., Zollner, G., Kaser, A., Tilg, H., Krause, R., Lammert, F., Langner, C., Zatloukal, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.009 · Cited by 468
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Bambha, K., Kim, W. R., Talwalkar, J., Torgerson, H., Benson, J. T., Therneau, T. M., Loftus, E. V., Yawn, B. P., Dickson, E. R., & Melton, L. J. (2003) · Gastroenterology · doi:10.1016/j.gastro.2003.07.011 · Cited by 450
Self-citationManns, M. P., Woynarowski, M., Kreisel, W., Lurie, Y., Rust, C., Zuckerman, E., Bahr, M. J., Günther, R., Hultcrantz, R. W., Spengler, U., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.046 · Cited by 442
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC
Corpechot, C., El Naggar, A., Poujol-Robert, A., Ziol, M., Wendum, D., Chazouillères, O., de Lédinghen, V., Dhumeaux, D., Marcellin, P., Beaugrand, M., et al. (2006) · Hepatology · doi:10.1002/hep.21151 · Cited by 441
A Revised Natural History Model for Primary Sclerosing Cholangitis
KIM, W. R., THERNEAU, T. M., WIESNER, R. H., POTERUCHA, J. J., BENSON, J. T., MALINCHOC, M., LARUSSO, N. F., LINDOR, K. D., & DICKSON, E. R. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64614-4 · Cited by 434
Self-citationPrevalence of Primary Sclerosing Cholangitis in Patients With Ulcerative Colitis
Olsson, R., Danielsson, Å., Järnerot, G., Lindström, E., Lööf, L., Rolny, P., Rydén, B.-O., Tysk, C., & Wallerstedt, S. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)70019-t · Cited by 426
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394 · cited 1×
“A European study did not show increased survival times of patients with PSC treated with 17–23 mg $ kg 1 $ day 1 UDCA compared with placebo.(102) However, this study was underpowered.”
BackgroundThe UK-PSCSC Consortium, Liu, J. Z., The International IBD Genetics Consortium, The International PSC Study Group, Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., Andreassen, O. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2616 · Cited by 391
Self-citationPrimary Sclerosing Cholangitis
(2007) · Gastroenterology Nursing · doi:10.1097/01.sga.0000267930.44372.16 · Cited by 382
Clinical diagnostic criteria of IgG4‐related sclerosing cholangitis 2012
Ohara, H., Okazaki, K., Tsubouchi, H., Inui, K., Kawa, S., Kamisawa, T., Tazuma, S., Uchida, K., Hirano, K., Yoshida, H., et al. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0521-y · Cited by 378
Recurrence of Primary Sclerosing Cholangitis Following Liver Transplantation
Graziadei, I. W., Wiesner, R. H., Batts, K. P., Marotta, P. J., LaRusso, N. F., Porayko, M. K., Hay, E. J., Gores, G. J., Charlton, M. R., Ludwig, J., et al. (1999) · Hepatology · doi:10.1002/hep.510290427 · Cited by 375
Self-citationKipp, B. R., Stadheim, L. M., Halling, S. A., Pochron, N. L., Harmsen, S., Nagorney, D. M., Sebo, T. J., Therneau, T. M., Gores, G. J., Groen, P. C. D., et al. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30281.x · Cited by 367
Self-citationGenome-Wide Association Analysis in Primary Sclerosing Cholangitis
Karlsen, T. H., Franke, A., Melum, E., Kaser, A., Hov, J. R., Balschun, T., Lie, B. A., Bergquist, A., Schramm, C., Weismüller, T. J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.046 · Cited by 361
Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis
Graziadei, I. W., Wiesner, R. H., Marotta, P. J., Porayko, M. K., Hay, E. J., Charlton, M. R., Poterucha, J. J., Rosen, C. B., Gores, G. J., LaRusso, N. F., et al. (1999) · Hepatology · doi:10.1002/hep.510300501 · Cited by 359
Self-citationA preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
Mitchell, S. A., Bansi, D. S., Hunt, N., Bergmann, K. V., Fleming, K. A., & Chapman, R. W. (2001) · Gastroenterology · doi:10.1053/gast.2001.27965 · Cited by 351
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339 · cited 1×
“Although tests for serum levels of CA 19-9 alone are not sensitive or specific enough to facilitate detection of cholangiocarcinoma, a cut-off of 130 U/mL in the absence of bacterial cholangitis detect cholangiocarcinoma with 79% sensitivity and 98% specificity.(129) The value of measuring serum CA 19-9 to detect asym…”
BackgroundSelf-citationPrimary sclerosing cholangitis: findings on cholangiography and pancreatography.
MacCarty, R. L., LaRusso, N. F., Wiesner, R. H., & Ludwig, J. (1983) · Radiology · doi:10.1148/radiology.149.1.6412283 · Cited by 333
Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis
Mendes, F. D., Jorgensen, R., Keach, J., Katzmann, J. A., Smyrk, T., Donlinger, J., Chari, S., & Lindor, K. D. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00772.x · Cited by 328
Self-citationCholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation
Boberg, K. M., Bergquist, A., Mitchell, S., Pares, A., Rosina, F., Broomé, U., Chapman, R., Fausa, O., Egeland, T., Rocca, G., et al. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202760373434 · Cited by 311
The natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305
Fickert, P., Wagner, M., Marschall, H., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., Zatloukal, K., Liu, J., Waalkes, M. P., Cover, C., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.018 · Cited by 300
Grant, A. J., Lalor, P. F., Hübscher, S. G., Briskin, M., & Adams, D. H. (2001) · Hepatology · doi:10.1053/jhep.2001.24231 · Cited by 297
Stiehl, A., Rudolph, G., Klöters-Plachky, P., Sauer, P., & Walker, S. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00251-3 · Cited by 293
Cancer surveillance in patients with primary sclerosing cholangitis
Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 292
Self-citationFunction and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein)
Oude Elferink, R. P. J., & Paulusma, C. C. (2007) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-006-0062-9 · Cited by 282
Kaplan, G. G., Laupland, K. B., Butzner, D., Urbanski, S. J., & Lee, S. S. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01103.x · Cited by 273
Incidence of primary sclerosing cholangitis: A systematic review and meta-analysis
Molodecky, N. A., Kareemi, H., Parab, R., Barkema, H. W., Quan, H., Myers, R. P., & Kaplan, G. G. (2011) · Hepatology · doi:10.1002/hep.24247 · Cited by 273
Eaton, J. E., Silveira, M. G., Pardi, D. S., Sinakos, E., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., et al. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.156 · Cited by 268
Self-citationPonsioen, C. Y., Vrouenraets, S. M. E., Prawirodirdjo, W., Rajaram, R., Rauws, E. A. J., Mulder, C. J. J., Reitsma, J. B., Heisterkamp, S. H., & Tytgat, G. N. J. (2002) · Gut · doi:10.1136/gut.51.4.562 · Cited by 268
Dave, M., Elmunzer, B. J., Dwamena, B. A., & Higgins, P. D. R. (2010) · Radiology · doi:10.1148/radiol.10091953 · Cited by 265
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease
Boonstra, K., van Erpecum, K. J., van Nieuwkerk, K. M. J., Drenth, J. P. H., Poen, A. C., Witteman, B. J. M., Tuynman, H. A. R. E., Beuers, U., & Ponsioen, C. Y. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22938 · Cited by 262
Melum, E., Franke, A., Schramm, C., Weismüller, T. J., Gotthardt, D. N., Offner, F. A., Juran, B. D., Laerdahl, J. K., Labi, V., Björnsson, E., et al. (2011) · Nature Genetics · doi:10.1038/ng.728 · Cited by 256
Self-citationGrant, A. J., Lalor, P. F., Salmi, M., Jalkanen, S., & Adams, D. H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07374-9 · Cited by 255
Elevated Serum IgG4 Concentration in Patients with Primary Sclerosing Cholangitis
Jaffe, D. L. (2007) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)70051-5 · Cited by 251
Induction and function of vascular adhesion protein-1 at sites of inflammation.
Salmi, M., Kalimo, K., & Jalkanen, S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.6.2255 · Cited by 245
Björnsson, E., Chari, S. T., Smyrk, T. C., & Lindor, K. (2007) · Hepatology · doi:10.1002/hep.21685 · Cited by 243
Self-citationHigh-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Self-citationInvited review: Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease
Medvedev, A. E., Sabroe, I., Hasday, J. D., & Vogel, S. N. (2006) · Journal of Endotoxin Research · doi:10.1177/09680519060120030201 · Cited by 227
Poupon, R. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70015-3 · Cited by 222
Färkkilä, M., Karvonen, A., Nurmi, H., Nuutinen, H., Taavitsainen, M., Pikkarainen, P., & Kärkkäinen, P. (2004) · Hepatology · doi:10.1002/hep.20457 · Cited by 218
MDR3 (ABCB4) Defects: A Paradigm for the Genetics of Adult Cholestatic Syndromes
Trauner, M., Fickert, P., & Wagner, M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960172 · Cited by 214
Small-duct primary sclerosing cholangitis: a long-term follow-up study
Angulo, P., Maor-Kendler, Y., & Lindor, K. D. (2002) · Hepatology · doi:10.1053/jhep.2002.33202 · Cited by 213 · cited 2×
“Patients with small duct PSC have symptoms and laboratory results similar to those of subjects with classic PSC.(49) However, patients with small duct PSC survive longer and have a lower cumulative risk of cholangiocarcinoma than patients with”
ResultSelf-citationParikh, A., Leach, T., Wyant, T., Scholz, C., Sankoh, S., Mould, D. R., Ponich, T., Fox, I., & Feagan, B. G. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21896 · Cited by 210
Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis
Björnsson, E., Boberg, K. M., Cullen, S., Fleming, K., Clausen, O. P., Fausa, O., Schrumpf, E., & Chapman, R. W. (2002) · Gut · doi:10.1136/gut.51.5.731 · Cited by 207
Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in sweden†
Lindkvist, B., Benito de Valle, M., Gullberg, B., & Björnsson, E. (2010) · Hepatology · doi:10.1002/hep.23678 · Cited by 206
Al Mamari, S., Djordjevic, J., Halliday, J. S., & Chapman, R. W. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.013 · Cited by 204
Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease
Medvedev, A. E., Sabroe, I., Hasday, J. D., & Vogel, S. N. (2006) · Journal of Endotoxin Research · doi:10.1179/096805106x102255 · Cited by 203
Oseini, A. M., Chaiteerakij, R., Shire, A. M., Ghazale, A., Kaiya, J., Moser, C. D., Aderca, I., Mettler, T. A., Therneau, T. M., Zhang, L., et al. (2011) · Hepatology · doi:10.1002/hep.24487 · Cited by 198
Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis
Kaya, M., Petersen, B. T., Angulo, P., Baron, T. H., Andrews, J. C., Gostout, C. J., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03690.x · Cited by 196
Self-citationIn primary sclerosing cholangitis, gallbladder polyps are frequently malignant
Buckles, D. C., Lindor, K. D., LaRusso, N. F., Petrovic, L. M., & Gores, G. J. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05677.x · Cited by 194
Self-citationGallbladder disease in patients with primary sclerosing cholangitis
Said, K., Glaumann, H., & Bergquist, A. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.019 · Cited by 193
Kaya, M., Angulo, P., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80004-5 · Cited by 193
Self-citationLithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice
Fickert, P., Fuchsbichler, A., Marschall, H.-U., Wagner, M., Zollner, G., Krause, R., Zatloukal, K., Jaeschke, H., Denk, H., & Trauner, M. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050404 · Cited by 188
Joo, M., Abreu-e-Lima, P., Farraye, F., Smith, T., Swaroop, P., Gardner, L., Lauwers, G. Y., & Odze, R. D. (2009) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318196d018 · Cited by 184
Verdonk, R. C., Dijkstra, G., Haagsma, E. B., Shostrom, V. K., Van den Berg, A. P., Kleibeuker, J. H., Langnas, A. N., & Sudan, D. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01333.x · Cited by 182
Katt, J., Schwinge, D., Schoknecht, T., Quaas, A., Sobottka, I., Burandt, E., Becker, C., Neurath, M. F., Lohse, A. W., Herkel, J., et al. (2013) · Hepatology · doi:10.1002/hep.26447 · Cited by 178
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis
Fosby, B. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i1.1 · Cited by 175 · cited 4×
“Typically, PSC recurs more than 90 days after liver transplantation.(122) Interestingly, a large study showed that patients with IBD and an intact colon were at increased risk for recurrence of PSC.”
BackgroundInfluentialEpidemiology of primary sclerosing cholangitis in Spain
Escorsell, A., Parés, A., Rodés, J., Solís-Herruzo, J. A., Miras, M., & Morena, E. D. L. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80240-8 · Cited by 174
Bangarulingam, S. Y., Bjornsson, E., Enders, F., Barr Fritcher, E. G., Gores, G., Halling, K. C., & Lindor, K. D. (2010) · Hepatology · doi:10.1002/hep.23277 · Cited by 173
Self-citationHLA class II haplotypes in primary sclerosing cholangitis patients from five European populations
Spurkland, A., Saarinen, S., Boberg, K. M., Mitchell, S., Broome, U., Caballeria, L., Ciusani, E., Chapman, R., Ercilla, G., Fausa, O., et al. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530502.x · Cited by 171
Serum autoantibodies in patients with primary sclerosing cholangitis
Angulo, P., Peter, J. B., Gershwin, M. E., DeSotel, C. K., Shoenfeld, Y., Ahmed, A. E. E., & Lindor, K. D. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80061-6 · Cited by 167
Self-citationIs There A Role for Liver Biopsy in Primary Sclerosing Cholangitis?
Burak, K. W., Angulo, P., & Lindor, K. D. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07401.x · Cited by 165
Self-citationCurrent and Future Anti-Fibrotic Therapies for Chronic Liver Disease
Rockey, D. C. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.07.011 · Cited by 163
Lankisch, T. O., Metzger, J., Negm, A. A., Voβkuhl, K., Schiffer, E., Siwy, J., Weismüller, T. J., Schneider, A. S., Thedieck, K., Baumeister, R., et al. (2011) · Hepatology · doi:10.1002/hep.24103 · Cited by 162
Stanich, P. P., Björnsson, E., Gossard, A. A., Enders, F., Jorgensen, R., & Lindor, K. D. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.12.008 · Cited by 161
Self-citationSatapathy, S. K., Sakhuja, P., Malhotra, V., Sharma, B. C., & Sarin, S. K. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04756.x · Cited by 160
Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H., Moustafa, T., Spirlı̀, C., Fuchsbichler, A., Gumhold, J., Silbert, D., Zatloukal, K., et al. (2009) · Hepatology · doi:10.1002/hep.22891 · Cited by 157
Etiopathogenesis of Primary Sclerosing Cholangitis
O'Mahony, C. A., & Vierling, J. M. (2006) · Seminars in Liver Disease · doi:10.1055/s-2006-933559 · Cited by 157
Terjung, B., Söhne, J., Lechtenberg, B., Gottwein, J. M., Muennich, M., Herzog, V., Mähler, M., Sauerbruch, T., & Spengler, U. (2009) · Gut · doi:10.1136/gut.2008.157818 · Cited by 153
Al‐Chalabi, T., Portmann, B. C., Bernal, W., McFarlane, I. G., & Heneghan, M. A. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03722.x · Cited by 152
Jrgensen, K. K., Grzyb, K., Lundin, K. E. A., Clausen, O. P. F., Aamodt, G., Schrumpf, E., Vatn, M. H., & Boberg, K. M. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21699 · Cited by 149
Eksteen, B., Mora, J. R., Shepherd, E. L., Henderson, N. C., Lee–Turner, L., Villablanca, E. J., Curbishley, S. M., Aspinall, A. I., von Andrian, U. H., & Adams, D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.02.046 · Cited by 149
Sheth, P., Santos, N. D., Seth, A., LaRusso, N. F., & Rao, R. K. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00582.2006 · Cited by 149
Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease
Takeda, K., Kojima, Y., Ikejima, K., Harada, K., Yamashina, S., Okumura, K., Aoyama, T., Frese, S., Ikeda, H., Haynes, N. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802702105 · Cited by 148
Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis
Wiesner, R. H., LaRusso, N. F., Dozois, R. R., & Beaver, S. J. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90926-1 · Cited by 148
Farrant, M. J., Doherty, D. G., Donaldson, P. T., Vaughan, R. W., Hayllar, K. M., Welsh, K. I., Eddleston, A. L. W. F., & Williams, R. L. (1992) · Hepatology · doi:10.1002/hep.1840160217 · Cited by 148
Increased prevalence of primary sclerosing cholangitis among first-degree relatives
Bergquist, A. M., Lindberg, G., Saarinen, S., & Broomé, U. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.10.011 · Cited by 146
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
Yoshiji, H., Noguchi, R., Kuriyama, S., Ikenaka, Y., Yoshii, J., Yanase, K., Namisaki, T., Kitade, M., Masaki, T., & Fukui, H. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00420.2004 · Cited by 146
Fevery, J., Verslype, C., Lai, G., Aerts, R., & Van Steenbergen, W. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9681-4 · Cited by 145
IgG4+ Plasma Cell Infiltrates in Liver Explants With Primary Sclerosing Cholangitis
Zhang, L., Lewis, J. T., Abraham, S. C., Smyrk, T. C., Leung, S. T., Chari, S. T., Poterucha, J. J., Rosen, C. B. B., Lohse, C. M., Katzmann, J. A., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181c6c09a · Cited by 143
The many faces of Janus kinase
Seavey, M. M., & Dobrzański, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.024 · Cited by 143
Metzger, J., Negm, A. A., Plentz, R. R., Weismüller, T. J., Wedemeyer, J., Karlsen, T. H., Dakna, M., Mullen, W., Mischak, H., Manns, M. P., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302047 · Cited by 143
Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease
Porayko, M. K., Wiesner, R. H., LaRusso, N. F., Ludwig, J., MacCarty, R. L., Steiner, B. L., Twomey, C. K., & Zinsmeister, A. R. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)91096-o · Cited by 139
Pathogenesis of primary sclerosing cholangitis
Pollheimer, M. J., Halilbasic, E., Fickert, P., & Trauner, M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.10.009 · Cited by 138
Wolf, J. M., Rybicki, L. A., & Lashner, B. A. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02650.x · Cited by 136
Silveira, M. G., Torok, N. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. L., & Lindor, K. D. (2008) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.14 · Cited by 135
Self-citationAbdalian, R., Dhar, P., Jhaveri, K. S., Haider, M. A., Guindi, M. M., & Heathcote, J. (2008) · Hepatology · doi:10.1002/hep.22073 · Cited by 134
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis
Triantos, C. K., Koukias, N. M., Nikolopoulou, V. N., & Burroughs, A. K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04822.x · Cited by 132
Xu, B., Broomé, U., Ericzon, B.-G., & Sumitran–Holgersson, S. (2002) · Gut · doi:10.1136/gut.51.1.120 · Cited by 132
HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis
Mehal, W. Z., Lo, Y. M. D., Wordsworth, B. P., Neuberger, J., Hübscher, S. G., Fleming, K. A., & Chapman, R. W. (1994) · Gastroenterology · doi:10.1016/s0016-5085(94)95085-7 · Cited by 131
Karrar, A., Broomé, U., Södergren, T., Jaksch, M., Bergquist, A. M., Björnstedt, M., & Sumitran–Holgersson, S. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.01.039 · Cited by 128
Björnsson, E., Chari, S. T., Silveira, M. G., Gossard, A. A., Takahashi, N., Smyrk, T. C., & Lindor, K. D. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181c9dac6 · Cited by 128
Self-citationBorchers, A. T., Shimoda, S., Bowlus, C. L., Keen, C. L., & Gershwin, M. E. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0167-2 · Cited by 128
Mitchell, S. A., Thyssen, M., Orchard, T. R., Jewell, D. P., Fleming, K. A., & Chapman, R. W. (2002) · Gut · doi:10.1136/gut.51.4.567 · Cited by 128
Colchicine treatment of primary sclerosing cholangitis
Olsson, R., Broomé, U., Danielsson, Å., Hägerstrand, I., Järnerot, G., Lööf, L., Prytz, H., Rydén, B.-O., & Wallerstedt, S. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90220-1 · Cited by 126
Review article: overlap syndromes and autoimmune liver disease
Trivedi, P. J., & Hirschfield, G. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05223.x · Cited by 126
A Double-blind, Placebo-controlled, Randomized Study of Infliximab in Primary Sclerosing Cholangitis
Hommes, D. W., Erkelens, W. G., Ponsioen, C. Y., Stokkers, P. C. F., Rauws, E. A., van der Spek, M., ten Kate, F. J. W., & van Deventer, S. J. H. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181662426 · Cited by 125
Is there a role for liver biopsy in primary sclerosing cholangitis?
Burak, K. W. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00105-9 · Cited by 125
Marelli, L., Xirouchakis, E., Kalambokis, G. N., Cholongitas, Ε., Hamilton, M., & Burroughs, A. K. (2011) · Gut · doi:10.1136/gut.2010.235408 · Cited by 121
He, H., Mennone, A., Boyer, J. L., & Cai, S.-Y. (2011) · Hepatology · doi:10.1002/hep.24047 · Cited by 119
Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis
Talwalkar, J. A., Angulo, P., Johnson, D. C., Petersen, B. T., & Lindor, K. D. (2004) · Hepatology · doi:10.1002/hep.20287 · Cited by 119
Self-citationLiaskou, E., Karikoski, M., Reynolds, G. M., Lalor, P. F., Weston, C. J., Pullen, N., Salmi, M., Jalkanen, S., & Adams, D. (2010) · Hepatology · doi:10.1002/hep.24085 · Cited by 118
The immunobiology of primary sclerosing cholangitis
Aron, J. H., & Bowlus, C. L. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0154-7 · Cited by 116
Fritcher, E. G. B., Kipp, B. R., Voss, J. S., Clayton, A. C., Lindor, K. D., Halling, K. C., & Gores, G. J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.272 · Cited by 112
Self-citationPohl, J., Ring, A., Stremmel, W., & Stiehl, A. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200601000-00012 · Cited by 111
Kaltenthaler, E., Vergel, Y. B., Chilcott, J. B., Thomas, S., Blakeborough, T., Walters, S. J., & Bouchier, H. (2004) · Health Technology Assessment · doi:10.3310/hta8100 · Cited by 110
HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis
Olerup, O., Olsson, R., Hultcrantz, R., & Broomé, U. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90463-8 · Cited by 108
Gallbladder disease in patients with primary sclerosing cholangitis
Brandt, D., MacCarty, R. L., Charboneau, J. W., LaRusso, N. F., Wiesner, R., & Ludwig, J. (1988) · American Journal of Roentgenology · doi:10.2214/ajr.150.3.571 · Cited by 108
Clinical profile of primary sclerosing cholangitis in Singapore
Ang, T. L., Fock, K. M., Ng, T. M., Teo, E. K., Chua, T. S., & Tan, J. Y. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02835.x · Cited by 107
Regan, M. M., Durie, P. R., Zielenski, J., Sheth, S. G., Shea, J. C., Bishop, M. D., Chopra, S., Malmberg, E., Walker, C., Ricci, R., et al. (2003) · Human Genetics · doi:10.1007/s00439-003-0963-z · Cited by 106
Pathologic Features and Evolution of Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Scheuer, P. J. (1998) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)63652-5 · Cited by 106
Fevery, J., Henckaerts, L., Oirbeek, R. V., Vermeire, S., Rutgeerts, P. J., Nevens, F., & Steenbergen, W. V. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02575.x · Cited by 105
Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment
Vieth, M., Behrens, H., & Stolte, M. (2006) · Gut · doi:10.1136/gut.2005.075531 · Cited by 105
Eaton, J. E., Thackeray, E. W., & Lindor, K. D. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.361 · Cited by 101
Self-citationExpression of the mucosal vascular addressin, MAdCAM‐1, in inflammatory liver disease
Hillan, K. J., Hagler, K. E., MacSween, R. N. M., Ryan, A. M., Renz, M. E., Chiu, H. H., Ferrier, R. K., Bird, G. L. A., Dhillon, A. P., Ferrell, L. D., et al. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00084.x · Cited by 99
Imam, M. H., Sinakos, E., Gossard, A. A., Kowdley, K. V., Luketic, V. A., Harrison, M. E., McCashland, T. M., Befeler, A. S., Harnois, D. M., Jorgensen, R. A., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04863.x · Cited by 96
Self-citationAtypical p-ANCA in PSC and AIH: A Hint Toward a “leaky gut”?
Terjung, B., & Spengler, U. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8088-8 · Cited by 93
Liver Transplantation in Primary Sclerosing Cholangitis
Bjøro, K., Brandsæter, B., Foss, A. E., & Schrumpf, E. (2006) · Seminars in Liver Disease · doi:10.1055/s-2006-933565 · Cited by 91
Mueller, T., Beutler, C., Picó, A. H., Shibolet, O., Pratt, D. S., Pascher, A., Neuhaus, P., Wiedenmann, B., Berg, T., & Podolsky, D. K. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02635.x · Cited by 90
Autoimmune pancreatitis and multiple bile duct strictures treated effectively with steroid
Kojima, E., Kimura, K., Noda, Y., Kobayashi, G., Itoh, K., & Fujita, N. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1108-1 · Cited by 89
Lindström, L., Boberg, K. M., Wikman, O., Friis–Liby, I., Hultcrantz, R., Prytz, H., Sandberg–Gertzén, H., Sangfelt, P., Rydning, A., Folvik, G., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04966.x · Cited by 89
Inflammatory Bowel Disease in Primary Sclerosing Cholangitis: A Robust yet Changing Relationship
Sinakos, E., Samuel, S., Enders, F., Loftus, E. V., Sandborn, W. J., & Lindor, K. D. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e3182802893 · Cited by 89
Self-citationSandanayake, N. S., Sinclair, J., Andreola, F., Chapman, M. H., Xue, A., Webster, G. J. M., Clarkson, A., Gill, A. J., Norton, I. D., Smith, R. C., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.376 · Cited by 86
Bacteriological and endotoxin studies in cases of ulcerative colitis submitted to surgery.
Palmer, K. R., Duerden, B. I., & Holdsworth, C. D. (1980) · Gut · doi:10.1136/gut.21.10.851 · Cited by 86
Scheuer, P. J. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.2.179 · Cited by 86
A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis
Bharucha, A. E., Jorgensen, R. A., Lichtman, S. N., LaRusso, N. F., & Lindor, K. D. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02324.x · Cited by 86
Self-citationAdeyi, O. A., Fischer, S. E., & Guindi, M. M. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.068254 · Cited by 85
Durieu, I., Pellet, O., Simonot, L., Durupt, S., Bellon, G., Durand, D. V., & Minh, V. A. T. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80259-1 · Cited by 84
A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis
Epstein, M. P., & Kaplan, M. M. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000011827.87103.2e · Cited by 83
Navaneethan, U., Venkatesh, P. G. K., Mukewar, S. S., Lashner, B. A., Remzi, F. H., McCullough, A. J., Kiran, R. P., Shen, B., & Fung, J. J. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.01.006 · Cited by 83
Review article: current management of primary sclerosing cholangitis
Cullen, S., & Chapman, R. W. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02407.x · Cited by 82
Lindström, L., Lapidus, A. B., Öst, Å., & Bergquist, A. M. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31822bbcc1 · Cited by 81
Welsh, F. K. S., & Wigmore, S. J. (2004) · Transplantation · doi:10.1097/01.tp.0000113807.74942.d2 · Cited by 77
Pregnancy in primary sclerosing cholangitis
Wellge, B. E., Sterneck, M., Teufel, A., Rust, C., Franke, A., Schreiber, S., Berg, T., Günther, R., Kreisel, W., zu Eulenburg, C., et al. (2011) · Gut · doi:10.1136/gut.2010.228924 · Cited by 76 · cited 1×
“Although no serious maternal outcomes were noted, there was an increase in liver enzyme levels among 20% of pregnant women with PSC.(11) The major risk factor for development of PSC is inflammatory bowel disease (IBD).”
BackgroundDistler, J. H. W., & Distler, O. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.120196 · Cited by 73
Management of Primary Sclerosing Cholangitis
Lee, Y., & Kaplan, M. M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05585.x · Cited by 71
Risk factors for complications of ERCP in primary sclerosing cholangitis
Ismail, S., Kylänpää, L., Mustonen, H. K., Halttunen, J., Lindström, O. K., Jokelainen, K., Udd, M., & Färkkilä, M. A. (2012) · Endoscopy · doi:10.1055/s-0032-1325677 · Cited by 69
Will we ever model PSC? – “It's hard to be a PSC model!”
Pollheimer, M. J., Trauner, M., & Fickert, P. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.04.014 · Cited by 66
Jørgensen, K. K., Lindström, L., Cvancarova, M., Castedal, M., Friman, S., Schrumpf, E., Foss, A., Isoniemi, H., Nordin, A., Holte, K., et al. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.685754 · Cited by 65
Thackeray, E. W., Charatcharoenwitthaya, P., Elfaki, D., Sinakos, E., & Lindor, K. D. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.020 · Cited by 61
Self-citationAlkhatib, A. A., Hilden, K., & Adler, D. G. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1830-8 · Cited by 60
Small duct cholangitis induced byn-formyll-methioninel-leucinel-tyrosine in rats
Yamada, S., Ishii, M., Liang, L., Yamamoto, T., & Toyota, T. (1994) · Journal of Gastroenterology · doi:10.1007/bf02365447 · Cited by 59
Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis
Goldberg, D. S., Camp, A., Martinez-Camacho, A., Forman, L., Fortune, B., & Reddy, R. K. (2013) · Liver Transplantation · doi:10.1002/lt.23587 · Cited by 58 · cited 1×
“However, the practice of referral for liver transplantation from a living donor or granting exception points for a perceived increased risk in mortality secondary to cholangitis was questioned by a study that did not find an increased risk of waitlist removal for death or clinical deterioration secondary to cholangiti…”
BackgroundFarnesoid X receptor agonists for primary biliary cirrhosis
Lindor, K. D. (2011) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834452c8 · Cited by 50
Self-citationWalker, M., & Radley, S. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0517-2 · Cited by 49
Current Trends in Living Donor Liver Transplantation for Primary Sclerosing Cholangitis
Goldberg, D. S., French, B. C., Thomasson, A. M., Reddy, K. R., & Halpern, S. D. (2011) · Transplantation · doi:10.1097/tp.0b013e31821694b3 · Cited by 44
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., Keach, J. C., LaRusso, N. F., & Lindor, K. D. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)85744-3 · Cited by 41
Self-citation[Incidence and prevalence of autoimmune liver diseases].
Berdal, J., Ebbesen, J., & Rydning, A. (1998) · PubMed · Cited by 41
Hepatobiliary injury associated with experimental small-bowel bacterial overgrowth in rats
Lichtman, S. N., & Sartor, R. B. (1991) · Immunologic Research · doi:10.1007/bf02919752 · Cited by 28
Eaton, J. E., Smyrk, T. C., Imam, M. H., Pardi, D. S., Loftus, E. V., Owens, V., & Talwalkar, J. A. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12469 · Cited by 22
Self-citation
Cited by
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Self-citationGlobal burden of liver disease: 2023 update
Devarbhavi, H., Asrani, S. K., Arab, J. P., Nartey, Y. A., Pose, E., & Kamath, P. S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.017 · Cited by 2,267
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505
Self-citationEpidemiology of gallbladder cancer
Rawla, P., Sunkara, T., Thandra, K. C., & Barsouk, A. (2019) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2019.85166 · Cited by 354
Metadata
- Authors
- Eaton, J. E., Talwalkar, J. A., Lazaridis, K. N., Gores, G. J., & Lindor, K. D.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 145
- Issue
- 3
- Pages
- 521-536
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2170004041
- Cited by
- 436
- References
- 174
- FWCI
- 19.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.